Patents by Inventor Christiane RADZIMSKI

Christiane RADZIMSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11835519
    Abstract: A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 5, 2023
    Assignees: EUROIMMUN Medizinische Labordiagnostika AG, Mayo Foundation for Medical Education and Research
    Inventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Stefanie Hahn, Christiane Radzimski, Mandy Unger, Andrew McKeon, Sean Pittock, Thomas Kryzer, Vanda Lennon, Josephe Honorat
  • Patent number: 11828758
    Abstract: A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: November 28, 2023
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Katja Steinhagen, Andrea Deerberg, Erik Lattwein, Christiane Radzimski, Jana Böthfür
  • Publication number: 20220317121
    Abstract: A method can be used for detecting, in a sample, an autoantibody binding to a polypeptide having the sequence SEQ ID NO: 1, SEQ ID NO: 11 or SEQ ID NO: 24. A carrier containing said polypeptide and an autoantibody binding to said polypeptide are useful. The autoantibody may be used for the diagnosis of a disease, and a method can be used for isolating an autoantibody binding to said polypeptide. The polypeptide and a kit containing said polypeptide are useful, and can be used for the manufacture of a kit or medical device. A method involves contacting a medical or diagnostic device containing said polypeptide with a buffered solution containing an antibody binding specifically to said polypeptide. A sample containing said autoantibody as a positive control and a diluted sample containing said autoantibody are useful.
    Type: Application
    Filed: March 23, 2022
    Publication date: October 6, 2022
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Zitao ZENG, Lars Komorowski, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christiane Radzimski, Nadine Rochow, Stefanie Brakopp
  • Publication number: 20220308053
    Abstract: A method involves detecting in a sample an autoantibody binding specifically to a mammalian VGLUT. An autoantibody binding specifically to a mammalian VGLUT and a diagnostically useful carrier with a solid phase with an immobilized polypeptide containing a mammalian VGLUT or a variant thereof, are useful. The autoantibody can be used for diagnosing a neurological autoimmune disease or a cancer.
    Type: Application
    Filed: March 25, 2022
    Publication date: September 29, 2022
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Ramona MISKE, Christiane Radzimski, Kathrin Margalene Borowski, Yvonne Denno
  • Patent number: 11208465
    Abstract: A polypeptide contains laminin beta-4 and a carrier contains the polypeptide. An antibody, preferably autoantibody, is against laminin beta-4. Furthermore, use of the polypeptide, carrier or autoantibody for the diagnosis of a disease, and a method with the step of detecting an autoantibody against laminin beta-4 in a sample are described.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: December 28, 2021
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Christian Probst, Christiane Radzimski, Lars Komorowski, Wolfgang Schlumberger, Winfried Stoecker, Detlef Zillikens, Christoph Hammers, Enno Schmidt, Stephanie Goletz
  • Publication number: 20210181196
    Abstract: A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 17, 2021
    Applicants: EUROIMMUN Medizinische Labordiagnostika AG, Mayo Foundation for Medical Education and Research
    Inventors: Ramona MISKE, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Stefanie Hahn, Christiane Radzimski, Mandy Unger, Andrew McKeon, Sean Pittock, Thomas Kryzer, Vanda Lennon, Josephe Honorat
  • Publication number: 20210033609
    Abstract: A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.
    Type: Application
    Filed: October 1, 2020
    Publication date: February 4, 2021
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Katja Steinhagen, Andrea Deerberg, Erik Lattwein, Christiane Radzimski, Jana Böthfür
  • Patent number: 10837963
    Abstract: A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO1 or a variant thereof, where the recombinant polypeptide is a monomer, a dimer, or a hexamer.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: November 17, 2020
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Katja Steinhagen, Andrea Deerberg, Erik Lattwein, Christiane Radzimski, Jana Böthfür
  • Publication number: 20200123230
    Abstract: A polypeptide contains laminin beta-4 and a carrier contains the polypeptide. An antibody, preferably autoantibody, is against laminin beta-4. Furthermore, use of the polypeptide, carrier or autoantibody for the diagnosis of a disease, and a method with the step of detecting an autoantibody against laminin beta-4 in a sample are described.
    Type: Application
    Filed: October 2, 2019
    Publication date: April 23, 2020
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Christian PROBST, Christiane Radzimski, Lars Komorowski, Wolfgang Schlumberger, Winfried Stoecker, Detlef Zillikens, Christoph Hammers, Enno Schmidt, Stephanie Goletz
  • Publication number: 20190383814
    Abstract: A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO1 or a variant thereof, where the recombinant polypeptide is a monomer, a dimer, or a hexamer.
    Type: Application
    Filed: February 22, 2017
    Publication date: December 19, 2019
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Katja STEINHAGEN, Andrea DEERBERG, Erik LATTWEIN, Christiane RADZIMSKI, Jana BÖTHFÜR